Loading...
•
Dec 31, 2019
Aytu BioScience Q2 2020 Earnings Report
Reported revenue increased and net loss decreased year-over-year, driven by the acquisition of Cerecor assets.
Key Takeaways
Aytu BioScience reported a 77% year-over-year increase in revenue, reaching $3.2 million for the quarter ended December 31, 2019. The net loss significantly decreased by 95% compared to the same quarter of the previous year, amounting to $0.2 million. These results reflect the partial contribution from the Cerecor assets acquired on November 1, 2019.
Reported revenue of $3.2 million, a 77% increase year-over-year and 121% sequentially.
Net loss decreased by 95% year-over-year to $0.2 million.
Closed on a $12.4 million prescription product portfolio purchase from Cerecor.
Launched Natesto co-promote with Acerus Pharmaceuticals and ZolpiMist co-promote with Validus Pharmaceuticals.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...